Stocks of Intra-Cellular Therapies - Current price, Where to buy? Chart
| Detail | Data |
|---|---|
| Stocks: | Intra-Cellular Therapies |
| ompany Name: | Intra-Cellular Therapies, Inc. |
| Ticker: | ITCI |
| Exchange: | NasdaqGS |
| Outstanding stocks: | 97,477,800 |
| 24-hour Volume: | 2,524,522 |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Number of Employees: | 610 |
| Country: | United States |
| City: | New York |
| Address: | 430 East 29th Street |
| P/E Ratio: | Forward P/E | EPS: | Forward EPS | Book value per share | Market capitalization |
|---|---|---|---|---|---|
| / | 67.27 | -1.46 USD | 1.14 USD | 6.14 USD | 7,475,572,736.00 USD |
| P/E Ratio: | / |
|---|---|
| Forward P/E: | 67.27 |
| EPS: | -1.46 USD |
| Forward EPS: | 1.14 |
| Book value per share: | 6.14 USD |
| Market capitalization: | 7,475,572,736.00 USD |
Intra-Cellular Therapies
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | 464,369,984.00 USD |
| Net Income: | -139,674,000.00 USD |
| Price-to-Book (P/B) Ratio: | 12.50 |
| PEG Ratio: | -1.15 |
Note: The data is approximate, subject to change over time, and may not be current; however, we strive for the highest possible accuracy.
Analysts' predictions
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation issued for Intra-Cellular Therapies stocks is: buy |
| Number of Analysts: | 15 |
| Highest Target Price: | 120 USD |
| Lowest Target Price: | 65 USD |
| Average Target Price: | 90 USD |
Note: The data is approximate. Recommendations and price forecasts for Intra-Cellular Therapies stocks based on analysts' ratings may change over time. Some recommendations may already be outdated and may not be accurate. We strongly advise against buying and selling stocks based on analysts' recommendations!
Dividend
| Dividends | Value |
|---|---|
| Dividend Amount | According to our data, the company Intra-Cellular Therapies is currently not paying dividends. |
| Annual Yield %: | - |
| Ex-dividend Date: | - |
| Average % Yield for 5 Years: | - |
| Payout Ratio: | - |
| Value of Last Dividend Paid: | - |
| Date of Last Dividend: | - |
The dividend is displayed for the entire calendar year, however, it is usually paid out quarterly in parts. Data may change!
Where to Buy Intra-Cellular Therapies Stocks?
If you're interested in investing in Intra-Cellular Therapies stocks and believe in their future growth, you can purchase them through stock brokers like XTB or eToro. To make buying easier, we've prepared a table with offers from these brokers, including quick purchase of Intra-Cellular Therapies stocks through mobile apps with client support. In this table, you can compare brokers offering real Intra-Cellular Therapies stocks. Brokers providing the option to buy real stocks (not CFDs) are identified by "Real Stocks" in the comparison table column.
| Broker | Platforms | Regulation | Min. Deposit | Deposits / Withdrawals | CopyTrader | Real Stocks | Website Link |
|---|---|---|---|---|---|---|---|
 |
Proprietary platform, social network + CopyTrader™ | 100 USD | Bank transfer, credit cards, Skrill, PayPal, Neteller |
 Go to eToro
|
|||
 |
xStation, mobile version | 10 USD | Credit cards, Skrill, bank transfer |
 Go to XTB
|
|
|
| xStation, mobile version | Proprietary platform, social network + CopyTrader™ |
|
Go to XTB
|
Go to eToro
|
More Information about Intra-Cellular Therapies (ITCI)
Revenues of 464,369,984.00 USD indicate room for growth and improvement for Intra-Cellular Therapies. This presents an opportunity for further development. Negative EBITDA of -158,852,992.00 USD may indicate challenges but also opportunities for Intra-Cellular Therapies to invest in future growth. Debt-to-equity ratio of 0.03 suggests that Intra-Cellular Therapies has a healthy financial structure and effectively manages its debts. This is key to stable growth. Gross margin of 53.94% shows that Intra-Cellular Therapies efficiently manages costs and maintains a high share of revenues. This is a sign of a strong market position. Lower profit margin of -30.08% suggests opportunities for Intra-Cellular Therapies to increase efficiency and reduce costs.
| Indicator | Value |
|---|---|
| Revenue, Debt, and Cash Flow | |
| Company Revenue: | 464,369,984.00 USD |
| EBITDA: | -158,852,992.00 USD - Negative EBITDA may signal financial challenges or growth investments. |
| Earnings Per Share: | -1.46 USD |
| Book Value Per Share: | 6.14 USD |
| Total Cash: | 497,940,992.00 USD |
| Total Cash per Share: | 5.14 USD |
| Total Debt: | 16,938,000.00 USD |
| Debt to Equity Ratio: | 0.03 |
| Quick Ratio: | 4.95 |
| Current Ratio: | 5.41 |
| Free Cash Flow: | -28,972,124.00 USD |
| Operating Cash Flow: | -124,199,000.00 USD |
| Company Margins | |
| Gross Margins: | 53.94 % |
| EBITDA Margins: | -34.21 % |
| Operating Margins: | -25.81 % |
| Profit Margins: | -30.08 % |
| Performance | |
| Return on Assets: | -13.4 % |
| Return on Equity: | -22.4 % |
| Earnings Growth (1 year): | / |
| Revenue Growth (1 year): | 50.3 % |
| Year-over-Year Quarterly Earnings Growth: | / |
| Valuation | |
| Market Capitalization: | 7,475,572,736.00 USD |
| Enterprise Value: | 6,943,140,352.00 USD |
| EV/Revenue: | 14.952 |
| EV/EBITDA: | -43.708 |
| Number of Shares and Short Shares | |
| Float Shares: | 94,593,211 shares |
| Shares Outstanding: | 97,477,800 shares |
| Held Percent Insiders: | 0.02 % |
| Held Percent Institutions: | 98.36 % |
| Shares Short: | 3,465,117 |
| Shares Short Prior Month: | 3,695,471 |
| Date Short Interest: | 2024-03-28 |
| Shares Percent Shares Out: | 3.58 % |
| Short Ratio: | 5.29 |
| Beta: | 1.02 |
| Short Percent of Float: | 4.15 % |
| Předpokládaný počet akcií: | 97,477,800 |
Frequently Asked Questions (FAQ)
According to our data, Intra-Cellular Therapies does not currently pay dividends, even in 2024.
Intra-Cellular Therapies shares are traded on the stock exchange NasdaqGS under the ticker symbol: ITCI. You can buy or trade them with a variety of stock brokers offering real stock trading services.
According to our data, there is a buy recommendation issued for Intra-Cellular Therapies shares by a total of 15 analysts. The average target price prediction is 90 USD per share.
The total number of Intra-Cellular Therapies shares on the exchange is 97,477,800.00, which, at the current market capitalization, values the company at 7,475,572,736.00 USD.
